Rapid Medical has enrolled the first patient in its COGNITIVE study, investigating the link between mechanical thrombectomy using their TIGERTRIEVER device and cognitive improvement in ischemic stroke patients. This study is the first of its kind to focus on the cognitive benefits of thrombectomy, with previous research primarily concentrating on motor function recovery. Dr. Fawaz Al-Mufti of Westchester Medical Center performed the first procedure in the study.
This research holds significant implications for stroke treatment. Up to 70% of stroke patients experience cognitive impairment, a debilitating consequence that significantly impacts quality of life. While current thrombectomy procedures improve motor function, understanding and potentially mitigating cognitive deficits represents a critical advancement in patient care and could reshape stroke treatment protocols. Positive results could lead to earlier and more aggressive intervention for stroke patients, emphasizing the cognitive preservation potential of this technology.
The COGNITIVE study will enroll up to 450 patients across 50 sites. It will include patients aged 18-75 presenting with a large vessel occlusion (LVO) treated with the TIGERTRIEVER device. TIGERTRIEVER is unique as an active stent retriever, allowing physicians to adjust the device intra-arterially for more precise clot removal and vessel protection. Previous trials comparing TIGERTRIEVER to other stent retrievers have shown faster procedure times, high first-pass revascularization rates, and positive clinical outcomes.
The COGNITIVE study’s findings could significantly impact the future of stroke care. Positive results could establish TIGERTRIEVER as a preferred treatment option for LVO stroke, emphasizing cognitive preservation alongside motor function recovery. This could lead to wider adoption of the device and a shift in the focus of stroke treatment, ultimately improving patient outcomes and quality of life after stroke. Furthermore, the study’s results could spur further research into the relationship between thrombectomy techniques and cognitive outcomes, leading to the development of even more refined and effective treatments.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
